Organigram (OGI.TO) stock price, revenue, and financials
Organigram market cap is C$478.5 m, and annual revenue was C$13.58 m in FY 2018
C$478.5 M
OGI.TO Mkt cap, 20-May-2022C$31.8 M
Organigram Revenue Q2, 2022Organigram Gross profit (Q2, 2022)6.9 M
Organigram Net income (Q2, 2022)-4 M
Organigram EBITDA (Q2, 2022)-8.2 M
Organigram EBIT (Q2, 2022)-15 M
Organigram Cash, 28-Feb-202282.3 M
Organigram EV404.1 M
Organigram Revenue Breakdown
Organigram revenue breakdown by business segment: 100.0% from PHARMACEUTICAL DIVERSIFIED
Organigram Income Statement
Annual
| CAD | FY, 2018 |
|---|---|
Revenue | 13.6m |
Cost of goods sold | (3.5m) |
Gross profit | 56.1m |
Operating expense total | (16.6m) |
Depreciation and amortization | (3.5m) |
EBITDA | 39.5m |
EBIT | 34.8m |
Interest expense | (10.1m) |
Pre tax profit | 26.2m |
Income tax expense | (5.7m) |
Net Income | 20.5m |
Quarterly
| CAD | Q2, 2022 |
|---|---|
Revenue | 31.8m |
Cost of goods sold | (25.0m) |
Gross profit | 6.9m |
R&D expense | (1.2m) |
Operating expense total | (14.6m) |
Depreciation and amortization | (3.4m) |
EBITDA | (8.2m) |
EBIT | (15.0m) |
Interest expense | (90.0k) |
Pre tax profit | (4.1m) |
Income tax expense | 97.0k |
Net Income | (4.0m) |
Organigram Balance Sheet
Annual
| CAD | FY, 2018 |
|---|---|
Cash | 55.1m |
Accounts Receivable | 793.0k |
Prepaid Expenses | 5.9m |
Inventories | 45.0m |
Current Assets | 203.2m |
PP&E | 98.6m |
Total Assets | 302.6m |
Accounts Payable | 10.8m |
Short-term debt | 421.0k |
Current Liabilities | 11.3m |
Long-term debt | 98.7m |
Non-Current Liabilities | 106.7m |
Total Debt | 99.2m |
Total Liabilities | 118.0m |
Common Stock | 157.8m |
Retained Earnings | 759.0k |
Total Equity | 184.6m |
Quarterly
| CAD | Q2, 2022 |
|---|---|
Cash | 82.3m |
Accounts Receivable | 23.0m |
Prepaid Expenses | 6.3m |
Inventories | 42.9m |
Current Assets | 236.6m |
PP&E | 233.6m |
Goodwill | 42.0m |
Total Assets | 585.1m |
Accounts Payable | 25.6m |
Short-term debt | 5.0m |
Current Liabilities | 47.0m |
Long-term debt | 2.9m |
Non-Current Liabilities | 24.8m |
Total Debt | 7.8m |
Total Liabilities | 71.7m |
Common Stock | 769.4m |
Retained Earnings | (281.0m) |
Total Equity | 513.4m |
Organigram Cash Flow
Annual
| CAD | FY, 2018 |
|---|---|
Net Income | 22.1m |
Depreciation and Amortization | 3.5m |
Accounts Receivable | 337.0k |
Inventories | (42.3m) |
Accounts Payable | 4.0m |
Cash From Operating Activities | (12.7m) |
Cash From Investing Activities | (98.0m) |
Long-term Borrowings | 107.6m |
Cash From Financing Activities | 163.9m |
Net Change in Cash | 53.1m |
Quarterly
| CAD | Q2, 2022 |
|---|---|
Net Income | (5.4m) |
Depreciation and Amortization | 12.1m |
Accounts Receivable | (1.1m) |
Inventories | (3.5m) |
Accounts Payable | (864.0k) |
Cash From Operating Activities | (10.1m) |
Cash From Investing Activities | 31.3m |
Long-term Borrowings | (42.0k) |
Cash From Financing Activities | 5.8m |
Net Change in Cash | 26.9m |
Organigram Ratios
| CAD | FY, 2018 |
|---|---|
Revenue/Employee | 38.2k |
Organigram Operating Metrics
Organigram's Patients was reported to be 18.1 k in Q1, 2020.
| Q1, 2017 | Q2, 2017 | Q3, 2017 | Q4, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q4, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q4, 2019 | Q1, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Average Selling Price per Gram (Dried Cannabis) | C$5.4 | C$5.36 | C$5.62 | C$4.57 | |||||||||
Brands | 5 | 5 | 5 | 4 | 4 | 3 | |||||||
Cannabis Harvested, kilograms | 8.32 k | 6.05 k | 7.43 k | 12.76 k | |||||||||
Cannabis Sold, kilogram and kilogram equivalents | 4.99 k | 4.62 k | 2.9 k | 5.5 k | |||||||||
Patients | 4 k | 4.04 k | 5.51 k | 7.4 k | 10.73 k | 12.96 k | 15.32 k | 15.73 k | 13.51 k | 14.88 k | 17 k | 17.2 k | 18.13 k |
